Avelumab becomes the first treatment for rare skin cancer metastatic Merkel Cell Carcinoma

BAVENCIO® (avelumab) becomes the first treatment for rare skin cancer metastatic Merkel Cell Carcinoma (mMCC) to be licensed for use in the UK.
 
The launch of avelumab marks a step-change in the way that mMCC, a rare and aggressive skin cancer, can be treated. Until now, the only treatment option for mMCC has been chemotherapy, which has limited efficacy and is not generally well-tolerated by people with mMCC.
 
Click here to read the article in full.